poster
Presented at: ASCO 2019
A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma
Register here for download
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
FixVUE, InSituPlex
Presented at SITC 2019.
Authors
Schwarze JK., Awada G., Cras L., Forsyth R., Dufait I., Van Reit I. and Neyns B.
Want to meet with us? Check out our upcoming events.
Related Content
Learn more
webinar
Introduction to Ultivue’s capabilities for immuno-oncology biomarker programs
Length: 20 minutes
Learn more
poster
Sequential same slide multiplex immunofluorescence and H&E staining for combined phenotypic and morphologic characterization of formalin-fixed paraffin-embedded tissue sections
Presented at AACR 2020
Learn more
poster
